Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TVGN Tevogen Bio Holdings

Trading 02-26 15:57:37 EST

0.2859

-0.0033

-1.14%

High0.2980	Low0.2749	Vol671.10K
Open0.2900	D1 Closing0.2892	Amplitude7.99%
Mkt Cap57.62M	Tradable Cap7.25M	Total Shares201.52M
T/O191.35K	T/O Rate2.65%	Tradable Shares25.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":0.2859,"timestamp":1772139396788,"preClose":0.2892,"halted":0,"volume":671104,"delay":0,"changeRate":-0.011410788381742825,"floatShares":25361700,"shares":201522282,"eps":-0.188139,"marketStatus":"Trading","change":-0.0033,"latestTime":"02-26 15:57:37 EST","open":0.29,"high":0.298,"low":0.2749,"amount":191346.19926912,"amplitude":0.079876,"askPrice":0.2897,"askSize":100,"bidPrice":0.2857,"bidSize":88,"shortable":3,"etf":0,"ttmEps":-0.188139,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.2892,"preHourTrading":{"tag":"盘前","latestPrice":0.297,"preClose":0.2892,"latestTime":"09:29 EST","volume":78483,"amount":24405.327964919998,"timestamp":1772116189874,"change":0.0078,"changeRate":0.026971,"amplitude":0.175657},"postHourTrading":{"tag":"盘后","latestPrice":0.2847,"preClose":0.2892,"latestTime":"19:46 EST","volume":11382,"amount":3261.6124,"timestamp":1772066817811,"change":-0.0045,"changeRate":-0.01556,"amplitude":0.018326},"volumeRatio":1.81009},"requestUrl":"/m/hq/s/TVGN","defaultTab":"news","newsList":[{"id":"2614020614","title":"BRIEF-Tevogen Signs LOI To Evaluate Potential Acquisition Of Sciometrix","url":"https://stock-news.laohu8.com/highlight/detail?id=2614020614","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614020614?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:55","pubTimestamp":1772132151,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Signs LOI To Evaluate Potential Acquisition Of SciometrixFeb 26 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN SIGNS LETTER OF INTENT TO EVALUATE POTENTIAL ACQUISITION OF SCIOMETRIX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2614502833","title":"Tevogen Signs LOI to Evaluate Sciometrix Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2614502833","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614502833?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115618,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has signed a non-binding, non-exclusive letter of intent to evaluate a potential acquisition of privately held Sciometrix Inc., developer of the Clinicus digital care management platform, that would leave Tevogen with a majority voting interest in Sciometrix if completed. Tevogen said it is exploring the deal to add digital care management and remote patient monitoring capabilities and to integrate Clinicus with its Tevogen.AI initiative, subject to due diligence and definitive agreements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLGyW34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4112","BK4588","TVGN","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","SG9999014005.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2614402940","title":"Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and Its Digital Care Management Platform Clinicus","url":"https://stock-news.laohu8.com/highlight/detail?id=2614402940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614402940?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2614028865","title":"Tevogen Bio Holdings Inc - Acquisition Would Give Tevogen Majority Voting Interest in Sciometrix","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614028865?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2614028807","title":"Tevogen Bio Holdings Inc - Deal Could Make Tevogen Revenue-Generating Healthcare Enterprise","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614028807?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2614547490","title":"Tevogen Bio Holdings Inc. Held Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2614547490","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614547490?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:01","pubTimestamp":1772056915,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. held a special meeting of stockholders on February 19, 2026. Stockholders approved an amendment to the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan to increase the number of shares available for issuance under the plan, and approved an amendment to the certificate of incorporation to authorize a reverse stock split at a ratio between 1:25 and 1:85, with the exact ratio to be set by the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsibl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL8Zk4RS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2607102674","title":"Press Release: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2607102674","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607102674?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:00","pubTimestamp":1769803200,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Jan. 30, 2026  -- Tevogen   today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets.Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors after a determination that a dividend would be the best use of Company capital at the time. No assurance can be given that a dividend will be declared, nor as to the timing or amount of any such dividend.Further updates will be provided as appropriate and in accordance with applicable disclosure requirements.This press release contains certain forward-looking statements, incl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4139","03160","BK4555","BK4585","BK4588","BK4099","TM","TVGN"],"gpt_icon":0},{"id":"2607532550","title":"Tevogen Bio Ties Long-Term Stock Incentives to Company Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2607532550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607532550?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:45","pubTimestamp":1769715913,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has announced an update to its long-term stock incentive program, modifying it to align awards with defined company milestones, including revenue. The revised program will apply to all employees, officers, directors, and consultants eligible under the company’s long-term incentives plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL9mX9k3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2604914945","title":"Tevogen Bio Holdings Inc. Announces Date for Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2604914945","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604914945?lang=en_us&edition=fundamental","pubTime":"2026-01-17 06:30","pubTimestamp":1768602631,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLyG0r5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2602272543","title":"Tevogen Bio Expands T Cell Therapy Pipeline and Boosts Manufacturing Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2602272543","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602272543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226427,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. announced significant scientific and operational milestones achieved in 2025, which were reported during the J.P. Morgan Healthcare Conference. The company advanced its proprietary ExacTcell platform, enhancing laboratory yields and supporting improved consistency and scalability for its cytotoxic T lymphocyte  therapies. Tevogen expanded its CTL pipeline to cover multiple high-value indications, including additional HLA restrictions for its SARS-CoV-2-specific product, Epstein-Barr virus  associated lymphomas, chronic hepatitis B, and HPV-related cancers. These advancements were supported by Tevogen.AI, the company’s analytics division, to aid in target discovery and prioritization. The updates reflect Tevogen's progress toward developing a scalable, multi-program cell therapy platform and establishing in-house GMP manufacturing capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3nbG5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","LU0820561818.USD","LU2023250504.SGD","LU0320765489.SGD","IE0034235303.USD","NDAQ","LU0882574139.USD","LU2756315318.SGD","IE00BJTD4V19.USD","LU1670628061.USD","LU0323591593.USD","LU0345769631.USD","LU0971096721.USD","LU0976567544.SGD","LU1496350171.SGD","LU2242649171.HKD","LU2746668461.USD","LU1363072403.SGD","LU0265550946.USD","LU1917777945.USD","BK4588","LU2430703178.SGD","LU1064131342.USD","IE00B1XK9C88.USD","LU1261432733.SGD","BK4207","LU2746668974.SGD","LU0345770308.USD","LU0942090050.USD","LU1084165304.USD","LU1366192091.USD","LU2210150020.SGD","LU1668664300.SGD","LU0820562030.AUD","LU2237443465.HKD","IE00BBT3K403.USD","BK4534","LU0211326755.USD","IE00B1BXHZ80.USD","LU1119994496.HKD","LU2023250330.USD","LU2210149790.SGD","LU0106261372.USD","LU2552382132.HKD","BK4585","BK4516","LU2237443895.HKD","LU0203345920.USD","LU1670627923.USD","LU2381873111.SGD"],"gpt_icon":0},{"id":"2584134477","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584134477","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584134477?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:23","pubTimestamp":1763644980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 08:23 ET (13:23 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALBT","BK4007","BK4211","LU0061474960.USD","LWLG","LU0203347892.USD","ARMK","LU2592432038.USD","LU2750360641.GBP","ALTS","ELDN","PNBK","WMT","LU2361044865.SGD","HP","LU2430703251.USD","OTLC","KALA","LU2468319806.SGD","BK4561","BRC","BYFC","UAVS","IE00B2B36J28.USD","IPAR","ASPI","LU0861579265.USD","MRK","LFMD","LU1430594728.SGD","SPRB","SRG","GPUS","LU1066053197.SGD","LU1974910355.USD","JJSF","PRPO","XP","IIIV","LU2023250843.SGD","TVGN","BK4152","AAME","RHEP","STI","TORM","NWBO","LU2430703178.SGD","LITS"],"gpt_icon":0},{"id":"2583686771","title":"Press Release: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583686771?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:32","pubTimestamp":1763148720,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 14, 2025  -- Tevogen  , today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry.Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the three months ended September 30, 2025, a reduction of 6% as compared to the three months ended September 30, 2024. The Company reported a 51% reduction in operating loss, totaling $21.5 million for the nine months ended September 30, 2025, compared to the same period in 2024.Tevogen Bio Holdings Inc. Unaudited Consolidated Statements of Operations. development      $ 3,110,752   $ 3,260,938   $  9,005,811   $ 28,196,970. The following tables present adjusted loss from operation, which is a non-GAAP financial measure that we define as loss from operations excluding stock-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2581706471","title":"Tevogen announces clinical milestone in evolution of ExacTcell platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706471?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:25","pubTimestamp":1762374358,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced a clinical milestone in the evolution of its proprietary ExacTcell platform: completion of T cell target identification fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-announces-clinical-milestone-in-evolution-of-exactcell-platform-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-announces-clinical-milestone-in-evolution-of-exactcell-platform-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2581706505","title":"Tevogen Bio Expands Precision T Cell Therapy Eligibility With Multi-HLA Targeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706505?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:20","pubTimestamp":1762374018,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has announced a significant clinical milestone in the development of its investigational precision T cell therapy, TVGN 489, designed for the treatment of acute and Long COVID. The company has completed T cell target identification for an additional five human leukocyte antigen  restrictions, broadening patient eligibility for its therapy. This advancement builds on a previously completed clinical trial of TVGN 489, which demonstrated 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patients. Results from this initial proof-of-concept trial were published in Blood Advances. TVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cells and aims to expand therapeutic access regardless of patients' genetic backgrounds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3blB8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","TVGN","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2581706587","title":"Tevogen Reports Major Clinical Milestone: Expands Hla Coverage of Its Investigational Precision T Cell Therapy for Acute and Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706587?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:20","pubTimestamp":1762374000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA9RJPJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2580247844","title":"Tevogen Bio Says Stockholders' Deficit is Under $9.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2580247844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580247844?lang=en_us&edition=fundamental","pubTime":"2025-11-04 04:16","pubTimestamp":1762200960,"startTime":"0","endTime":"0","summary":"Tevogen Bio said its total stockholders' deficit is less than $9.5 million, despite including in financial statements that it had an accumulated deficit of $129 million.The biotechnology company's financial statements presented for the quarter ended June 30 showed a deficit of $129 million, but with certain adjustments, that amount falls below $9.5 million, Chief Financial Officer Kirti Desai said Monday.Backing out the cash balance, the total cash loss to date is a little over $41 million and the remaining balance represents non-cash expenses of about $88 million. That is further offset by a credit of $110 million in additional paid-in capital. The company is also factoring in a capital raise amount of more than $8.8 million.Tevogen had raised total cash of under $42 million as of June 30.Tevogen plans to share a clearly labeled, fully reconciled set of adjusted financial metrics following its third-quarter filing, it said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2580242570","title":"Tevogen Bio Holdings Inc - Gaap Financials for Qtr Show $129 Mln Accumulated Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2580242570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580242570?lang=en_us&edition=fundamental","pubTime":"2025-11-04 03:46","pubTimestamp":1762199161,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2575756840","title":"BRIEF-Tevogen Says Actively Preparing For Next Stage Of Development Of TVGN 489","url":"https://stock-news.laohu8.com/highlight/detail?id=2575756840","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575756840?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:56","pubTimestamp":1760558182,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Says Actively Preparing For Next Stage Of Development Of TVGN 489Oct 15 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO HOLDINGS INC - TO COLLABORATE TO EXPEDITE DEVELOPMENT OF T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2DR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2575375688","title":"Tevogen: Intends to Collaborate With Govt Initiatives, Long Covid Patient Organizations, Healthcare Providers to Expedite Development of Tvgn 489","url":"https://stock-news.laohu8.com/highlight/detail?id=2575375688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575375688?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:52","pubTimestamp":1760557947,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2DR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://semperparatusspac.com","stockEarnings":[{"period":"1week","weight":0.0433},{"period":"1month","weight":-0.1406},{"period":"3month","weight":-0.3988},{"period":"6month","weight":-0.6822},{"period":"1year","weight":-0.759},{"period":"ytd","weight":-0.1265}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.040664},{"month":2,"riseRate":0.6,"avgChangeRate":0.065473},{"month":3,"riseRate":0.5,"avgChangeRate":-0.166085},{"month":4,"riseRate":0.5,"avgChangeRate":-0.189171},{"month":5,"riseRate":0.25,"avgChangeRate":0.008552},{"month":6,"riseRate":0.25,"avgChangeRate":-0.034979},{"month":7,"riseRate":0.5,"avgChangeRate":-0.078575},{"month":8,"riseRate":0.5,"avgChangeRate":-0.064152},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.111833}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction